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There is increasing evidence that de novo methylation of
promoter-associated CpG islands, contributes to the alteration of
gene expression in cancer (reviewed by Baylin et al, 1998). During
the development of colon cancer, methylation of CpG islands has
been reported in a number of genes including the calcitonin gene
(Silverman et al, 1989), the oestrogen receptor gene (Issa et al,
1994), the mismatch repair gene hMLH1 (Kane et al, 1997), the
MyoD gene (Myf-3) (Iacopetta et al, 1997) and the APC gene
(Hiltunen et al, 1997). More recently, a progressive increase in
methylation was also detected at some of these loci in normal
colonic mucosa as a consequence of aging (Ahuja et al, 1998).
In the studies that examined gene expression, methylation of the
CpG islands was associated with gene silencing.
In the colon, apoptosis contributes to the homeostasis of the
epithelial layer of the mucosa, which has a rapid rate of cell
turnover (Hall et al, 1994). Apoptosis is also responsible for the
removal of colonocytes with potentially oncogenic DNA damage.
Resistance of colonocytes to apoptosis may allow hyperprolifera-
tion, accumulation of oncogenic mutations and prevent killing of
malignant cells by chemotherapeutic agents. Abnormal patterns of
expression of a number of apoptosis-related genes have been
reported in both benign and malignant colonic tumours (reviewed
in Butler et al, 1999); however, molecular mediators of resistance
to apoptosis remain to be identified.
The Fas antigen is a widely expressed cell surface receptor.
Ligation of Fas by its endogenous ligand or by agonistic anti-
bodies, triggers rapid apoptosis (Trauth et al, 1989; Yonehara et al,
1989). The epithelial layer of the normal colonic mucosa expresses
Fas protein at high levels from the bottom of the crypts to the
luminal surface (Leithauser et al, 1993; Moller et al, 1994).
Expression of Fas in the colon is progressively reduced during the
transformation of normal epithelium to benign neoplasms, adeno-
carcinomas and ultimately, to metastases (Leithauser et al, 1993;
Moller et al, 1994). Loss of Fas activity could be a contributing
factor to the reduction in apoptotic capacity of colonic carcinomas.
In a previous study (Butler et al, 1998), we showed that the loss of
expression of Fas protein was reflected in a loss of Fas mRNA in
the majority of samples of colorectal carcinoma. However, allelic
loss of the Fas gene was a relatively rare event, being detected in
only 16% of carcinomas and reflecting the rate of loss of the entire
chromosome arm, 10 q, in colorectal carcinoma (Vogelstein et al,
1989). Similarly, gross gene rearrangements were not detected in
any of the colorectal carcinomas, raising the possibility that epi-
genetic events, including DNA methylation, could be responsible
for the loss of expression of Fas.
The human Fas gene contains a 650 bp GC-rich CpG island
spanning the 5¢ regulatory region and the first exon (Behrmann
et al, 1994; Cheng et al, 1995; Rudert et al, 1995), suggesting that
transcription of the gene may be regulated by methylation of the
CpG cytosine residues. The aim of this study was to determine the
methylation status of the promoter and exon 1 of the Fas gene in
DNA isolated from colorectal tumours with varying levels of
expression of Fas mRNA.
MATERIALS AND METHODS
Patients and samples
Forty-seven specimens of primary colonic or rectal tumours,
consisting of six adenomas and 41 carcinomas plus six samples of
macroscopically normal colonic mucosa, were obtained with
informed consent from 44 patients undergoing colonic resections.
The Dukes grades of the carcinomas are shown in Table 1.
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PCR primers 5Prom1 (5¢-TCCTGTACCCAGGCAGGAC) and
3Prom2 (5¢-ATCCCCGGGACTAAGACGG) were designed to
amplify a 655 base pair (bp) region spanning part of the promoter
and exon one of the human Fas gene (Figure 1). The probe was
amplified from normal genomic DNA by an initial denaturation of
5 min at 94°C, followed by 35 cycles of denaturation for 1 min at
94°C, annealing for 1 min at 58°C and extension for 90 s at 72°C;
with a final extension of 5 min at 72°C. The PCR product was
cloned into the pGEM-T plasmid vector (Promega, Madison, WI,
USA) and the identity of the product confirmed by DNA
sequencing. To generate a probe for Southern blotting, the Fas
gene insert was amplified from the Fas-pGEM plasmid using
5Prom1 and 3Prom2 primers, under the same amplification
conditions.
Southern blotting using methylation-sensitive
restriction enzymes
Ten micrograms of genomic DNA, isolated from colorectal
tumours or normal mucosa, was digested with TaqI (New England
Biolabs, Beverley, MA, USA), for 3 h or overnight at 65°C. DNA
was ethanol-precipitated before re-digesting with HpaII, MspI
(New England Biolabs) or CfoI (Boehringer Mannheim). Digests
were electrophoresed through 1.8% or 1.5% agarose gels and
blotted onto Genescreen Plus membranes (Dupont, Boston, MA,
USA). Membranes were hybridized with the 32P-labelled probe for
16 h at 42°C in 50% formamide, washed to a final stringency of
0.1 ´ SSC (standard saline citrate) and 0.1% sodium dodecyl
sulphate (SDS) at 68°C and the hybridization signals detected by
autoradiography.
RESULTS
The methylation status of the 5¢ regulatory region and exon 1 of
the Fas gene was initially examined by Southern blotting of DNA
following digestion with the restriction enzymes MspI and HpaII.
Both of these enzymes recognize the same DNA sequence
(CCGG); however, HpaII will not cut the sequence if the internal
cytosine residue is methylated. Six HpaII/MspI sites are present in
the region spanning the three putative transcriptional start sites
within the first exon of the Fas gene (Cheng et al, 1995) (Figure
1). A second enzyme, CfoI, was also used to assess the methyla-
tion status of a further five CpG sites in this region (Figure 1). CfoI
cleaves the sequence GCGC, but is inactive if the central C is
methylated. A Fas gene probe was generated by polymerase chain
reaction (PCR) amplification and its identity confirmed by
sequencing (Cheng et al, 1995).
The DNA was initially digested with TaqI, which flanked five
of the HpaII sites as well as four of the CfoI sites. The recognition
sequence of TaqI (TCGA) contains a CpG dinucleotide; however,
TaqI is not methylation-sensitive (Streeck, 1980). Digestion of
normal DNA (isolated from peripheral blood lymphocytes) with
the flanking enzyme, TaqI, alone, produced a band of 1 kb when
hybridized with the Fas probe (Figures 2 and 3). A second band of
approximately 5 kb in size was also detected, arising from binding
of the probe to sequences upstream of the TaqI site in the Fas
promoter.
When the TaqI-digested normal DNA was digested with MspI,
bands of 300 bp and 115 bp were observed, as well as the 5 kb
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Table 1 Clinical stages of carcinomas analysed for methylation status of the
Fas gene
Dukes’ grade Number of specimens
A3
B2 3
C1 2
D2
Unclassified 1
Probe
5´
T C C H T H CC H H C H H C T
3´
–320 –156 –74 –67 –200
Taql/Cfol
Taql
Hpall
Taql
90 bp 122 bp 115 bp 320 bp
5 kb 115 bp 300 bp
5 kb 1 kb
Figure 1 Restriction map of the 5¢ regulatory region and exon 1 of the human Fas gene. T = TaqI site, H = HpaII site, C = CfoI site. The asterisks denote the
major three transcription start sites (Cheng et al, 1995) and the hatched box denotes exon 1. The sizes of the major DNA restriction fragments are shown
underneath the map and the location of the 655 bp Fas probe is shown above the map. The 5¢ end of the probe detects an approximately 5 kb TaqI fragment.
Only the 1957 bp section directly upstream of the first transcription start site has been sequenced (Cheng et al, 1995, Rudert et al, 1995)band previously observed following digestion with TaqI alone
(Figure 2). According to a restriction map of the Fas promoter and
exon 1, digestion of the 1 kb TaqI fragment with MspI and probing
with the 655 bp Fas probe, should produce DNA fragments of 300,
115, 47, 43 and 28 bp (Figure 1). The smallest three fragments
could not be detected by Southern analysis. The methylation status
of the 1 kb region could then be determined by digestion of DNA
with TaqI and HpaII. If the sequence was fully methylated, HpaII
would not cut the DNA and the banding pattern would be the same
as that of TaqI alone. An unmethylated sequence would be
completely digested by HpaII and the banding pattern would be
the same as digestion with TaqI and MspI. A partially methylated
sequence would give rise to bands of intermediate size.
There are no MspI sites in the 1957 bp of known sequence
upstream of the first transcription start site (Cheng et al, 1995;
Rudert et al, 1995). Since there was no detectable change in the
size of the 5 kb band following digestion with both TaqI and MspI,
it can be deduced that there are probably no MspI sites in the
undefined upstream sequence (Figure 1).
Forty-eight samples of DNA isolated from colonic carcinomas
plus six adenomas were analysed for methylation of the HpaII
sites. These samples included a range of tumour grades (Table 1).
Two of the patients had both an adenoma and carcinoma analysed
and one patient had both a primary tumour and a metastatic
deposit. Digestion of the DNA samples with TaqI and HpaII
produced the same banding pattern as digestion with TaqI and
MspI. The HpaII sites were therefore not methylated in any of the
tumour samples analysed (Figure 2). There was also no evidence
of Fas methylation in six samples of DNA isolated from normal
colorectal mucosa.
Nineteen of the carcinomas were also assessed for methylation
at the CfoI sites (Figure 3), however, none of these sites were
methylated in any of the tumours tested. Digestion of DNA with
TaqI and CfoI gives rise to bands of 320, 122, 115 and 90 bp in
size. The 90-bp band was detected in the more-heavily-loaded
tracks and the 122 and 115 bp bands coincided on the blots. No
5 kb band was detected in CfoI/TaqI-digested DNA, confirming
that the CfoI site located 156 bp upstream of the first transcription
start site is unmethylated in all samples tested. There is a further
CfoI site 320 bp upstream of the first transcription start site (Figure
1) but the methylation status of this site can not be analysed as the
probe does not cover this region.
Seventeen of the tumours used in this study have previously
been analysed by Northern blotting for expression of Fas mRNA
(Butler et al, 1998). Nine of the tumours expressed normal levels
of Fas mRNA, five had reduced levels and, in two samples, Fas
mRNA could not be detected. This study probably underestimated
the loss of Fas as most tumours also contained normal tissue.
DISCUSSION
Cancer arises from the accumulation of multiple genetic and
epigenetic events in cellular DNA. These alterations can cause the
aberrant expression of genes involved in the regulation of cell
death, adhesion and proliferation. Methylation of CpG residues in
the 5¢ regulatory regions of tumour suppressor genes may be a
mechanism by which cellular proliferation can be deregulated
without genetic mutations (reviewed in Baylin et al, 1998). In
colon cancer, alterations in global methylation patterns are among
the earliest abnormalities to occur during the development of the
disease (Goelz et al, 1985). The studies presented above indicate
that the Fas gene promoter is consistently unmethylated in
colorectal tumours and normal mucosa. This suggests that methyl-
ation of the Fas promoter is not involved in the transcriptional
silencing of the Fas gene in colon tumours.
Screening samples of DNA for cytosine methylation using
restriction enzymes only examines a proportion of the total CpG
dinucleotides in a CpG island. There are 31 CpG sites in the
655 bp region of the Fas promoter and exon 1 spanned by the Fas
probe in the present study (Cheng et al, 1995). The HpaII and CfoI
sites examined in the present study represent nine of them, or 29%.
One of the HpaII sites in the promoter region is 20 bp upstream of
the first transcription start site. Any CpG methylation at this site
might interfere with binding of RNA polymerase and inhibit tran-
scription of the Fas gene. It is possible that de novo methylation of
the Fas promoter region does not involve all CpG sites and that
selective methylation of the CpG island is sufficient for the regula-
tion of transcription factor binding. Further studies using other
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Figure 2 Southern analysis of the Fas gene promoter from colorectal
tumours for changes in methylation. The blot was hybridized with a 655 bp
probe spanning five HpaII sites, in the promoter and first intron of the human
Fas gene. Lane 1 contains normal genomic DNA digested with TaqI, lane 2
contains the same DNA digested with TaqI and MspI, while lanes 3–9
contain individual samples of DNA from colonic tumours, digested with 
TaqI and HpaII
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Figure 3 Southern analysis of the Fas gene promoter from colorectal
tumours for changes in methylation. The blot was hybridized with a 655 bp
probe spanning five HpaII sites and four CfoI sites in the promoter and first
intron of the human Fas gene. Lane 1 contains genomic DNA digested with
TaqI only and lanes 2–13 contain samples of DNA from colonic tumours,
digested with TaqI and CfoI (odd numbered lanes) or TaqI and HpaII (even
numbered lanes)methodologies, including genomic sequencing using bisulphite
modification, which determines the methylation status of all
cytosines in a sequence (Frommer et al, 1992), are required to
totally exclude methylation that is restricted to a small region.
Other mechanisms must therefore be considered to account for
the frequent loss of expression of the Fas protein in colorectal
carcinoma. One mechanism for loss of Fas expression is that
expression or function of an essential transcription factor has been
altered. The promoter region of the Fas gene contains binding sites
for several transcriptional regulatory factors, including c-myb,
p53, NF-kB and Sp-1 (Behrmann et al, 1994; Cheng et al, 1995;
Rudert et al, 1995). An essential role has recently been demon-
strated for a composite Sp1/NF-kB-binding site in the Fas
promoter, in activating the expression of Fas mRNA in Jurkat cells
(Chan et al, 1999). Futher studies will be required to investigate
the hypothesis that defects in Sp1/NF-kB activity could account
for loss of expression of Fas in colorectal carcinomas.
A potential candidate for the regulation of the activity of the Fas
gene is p53, which, when expressed in tumour cells, induces the
expression of Fas mRNA (Owen-Schaub et al, 1995). Expression
of wild-type p53 in colon cancer cells renders them sensitive to
Fas-mediated apoptosis (Tamura et al, 1995) and certain genotoxic
treatments induce cell surface expression of Fas only in cells with
wild-type p53 genes (Matsumoto et al, 1996; Muller et al, 1997;
Reap et al, 1997; Reinke and Lozano, 1997; Sheard et al, 1997).
Taken together, these studies indicate that the Fas gene is a target
of p53-mediated transactivation. Inactivation of the p53 gene by
mutation and/or allelic loss occurs in up to 75% of colorectal
carcinomas (Baker et al, 1990), a similar frequency to loss of Fas
expression (Moller et al, 1994; Butler et al, 1998). Loss of Fas
expression may therefore be a consequence of p53 inactivation in
most colorectal tumours. The activity of histone acetyltransferases
and deacetylases is also vital in regulating gene regulation
(reviewed in Kuo and Allis, 1998) and alterations in the activity of
these enzymes might also play a role in the silencing of the Fas
gene in colorectal carcinoma. Further studies are required to define
the molecular mechanisms controlling expression of the Fas gene
and to determine the nature and significance of the defects in Fas
expression in colorectal carcinoma.
ACKNOWLEDGEMENTS
LMB was supported by an Australian Postgraduate Research
Scholarship and by supplementary funding from The Queen
Elizabeth Hospital Research Foundation. TB was supported by an
Australian Postgraduate Research Scholarship. We wish to thank
Mr Peter Hewett for providing the clinical samples.
REFERENCES
Ahuja N, Li Q, Mohan AL, Baylin SB and Issa J-PJ (1998) Aging and DNA
methylation in colorectal mucosa and cancer. Cancer Res 58: 5489–5494
Baker SJ, Markowitz S, Fearon ER, Willson JKV and Vogelstein B (1990)
Suppression of human colorectal carcinoma cell growth by wild-type p53.
Science 249: 912–915
Baylin SB, Herman JG, Graff JR, Vertino PM and Issa J-P (1998) Alterations in
DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 72:
141–196
Behrmann I, Walczak H and Krammer PH (1994) Structure of the human APO-1
gene. Eur J Immunol 24: 3057–3062
Butler LM, Hewett PJ, Butler WJ and Cowled PA (1998) Down-regulation of Fas
gene expression in colon cancer is not a result of allelic loss or gene
rearrangement. Br J Cancer 77: 1454–1459
Butler LM, Hewett PJ, Fitridge RA and Cowled PA (1999) Deregulation of
apoptosis in colorectal cancer: theoretical and therapeutic implications.
Aust NZ J Surg 69: 88–94
Chan H, Bartos DP and Owen-Schaub LB (1999) Activation-dependent
transcriptional regulation of the human Fas promoter requires NF-kappaB
p50-p65 recruitment. Mol Cell Biol 19: 2098–2108
Cheng J, Liu C, Koopman WJ and Mountz JD (1995) Characterization of human
Fas gene. J Immunol 154: 1239–1245
Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, Grigg GW, Molloy PL
and Paul CL (1992) A genomic sequencing protocol that yields a positive
display of 5-methylcytosine residues in individual DNA strands. Proc Natl
Acad Sci USA 89: 1827–1831
Goelz SE, Vogelstein B, Hamilton SR and Feinberg AP (1985) Hypomethylation of
DNA from benign and malignant human colon neoplasms. Science 228:
187–190
Hall PA, Coates PJ, Ansari B and Hopwood D (1994) Regulation of cell number in
the mammalian gastrointestinal tract: the importance of apoptosis. J Cell Sci
107: 3569–3577
Hiltunen MO, Alhonen L, Koistinaho J, Myöhänen S, Pääkkönen M, Marin S,
Kosma V-M and Jänne J (1997) Hypermethylation of the APC (adenomatous
polyposis coli) gene promoter region in human colorectal carcinoma. Int J
Cancer 70: 644–648
Iacopetta BJ, Harmon D, Spagnolo DV, House AK and Kay PH (1997)
Hypermethylation of the Myf-3 gene in human colorectal cancer. Anticancer
Res 17: 429–432
Issa J-P, Ottaviano YL, Celano P, Hamilton SR, Davidson NE and Baylin SB (1994)
Methylation of the oestrogen receptor CpG island links ageing and neoplasia in
human colon. Nat Genet 7: 536–540
Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, Jessup JM and
Kolodner R (1997) Methylation of the hMLH1 promoter correlates with
lack of expression of hMLH1 in sporadic colon tumors and mismatch
repair-defective human tumor cell lines. Cancer Res 57: 808–811
Kuo MH and Allis CD (1998) Roles of histone acetyltransferases and deacetylases
in gene regulation. Bioessays 20: 615–626
Leithäuser F, Dhein J, Mechtersheimer G, Koretz K, Brüderlein S, Henne C,
Schmidt A, Debatin K-M, Krammer PH and Möller P (1993) Constitutive
and induced expression of APO-1, a new member of the nerve growth
factor/tumor necrosis factor receptor superfamily, in normal and neoplastic
cells. Lab Invest 69: 415–429
Matsumoto Y, Hayakawa A, Tamada Y, Mori H and Ohashi M (1996) Upregulated
expression of Fas antigen on cultured human keratinocytes with induction of
apoptosis by cisplatin. Arch Dermatol Res 288: 267–269
Möller P, Koretz K, Leithauser F, Brüderlein S, Henne C, Quentmeier A and
Krammer PH (1994) Expression of APO-1 (CD95), a member of the NGF/TNF
receptor superfamily, in normal and neoplastic colon epithelium. Int J Cancer
57: 371–377
Muller M, Strand S, Hug H, Heinemann E-M, Walczak H, Hofmann WJ, Stremmel
W, Krammer PH and Galle PR (1997) Drug-induced apoptosis in hepatoma
cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and
involves activation of wild-type p53. J Clin Invest 99: 403–413
Owen-Schaub LB, Zhang W, Cusack JC, Angelo LS, Santee SM, Fujiwara T, Roth
JA, Deisseroth AB, Zhang W-W, Kruzel E and Radinsky R (1995) Wild-type
human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression.
Mol Cell Biol 15: 3032–3040
Reap EA, Roof K, Maynor K, Borrero M, Booker J and Cohen PL (1997) Radiation
and stress-induced apoptosis: a role for Fas/Fas ligand interactions. Proc Natl
Acad Sci USA 94: 5750–5755
Reinke V and Lozano G (1997) The p53 targets mdm2 and Fas are not required as
mediators of apoptosis in vivo. Oncogene 15: 1527–1534
Rudert F, Visser E, Forbes L, Lindridge E, Wang Y and Watson J (1995)
Identification of a silencer, enhancer, and basal promoter region in the human
CD95 (Fas/APO-1) gene. DNA Cell Biol 14: 931–937
Sheard MA, Vojtesek B, Janakova L, Kovarik J and Zaloudik J (1997) Up-regulation
of Fas (CD95) in human p53wild-type cancer cells treated with ionizing radiation.
Int J Cancer 73: 757–762
Silverman AL, Park J-G, Hamilton SR, Gazdar AF, Luk GD and Baylin SB (1989)
Abnormal methylation of the calcitonin gene in human colonic neoplasms.
Cancer Res 49: 3468–3473
Streeck RE (1980) Single-strand and double-strand cleavage at half-modified and
fully modified recognition sites for the restriction nucleases Sau3A and TaqI.
Gene 12: 267–275
Tamura T, Aoyama N, Saya H, Haga H, Futami S, Miyamoto M, Koh T, Ariyasu T,
Tachi M, Kasuga M and Takahashi R (1995) Induction of Fas-mediated
apoptosis in p53-transfected human colon carcinoma cells. Oncogene 11:
1939–1946
134 LM Butler
British Journal of Cancer (2000) 82(1), 131–135 © 2000 Cancer Research CampaignTrauth BC, Klas C, Peters AMJ, Matzku S, Möller P, Falk W, Debatin K-M and
Krammer PH (1989) Monoclonal antibody-mediated tumor regression by
induction of apoptosis. Science 245: 301–304
Vogelstein B, Fearon ER, Kern SE, Hamilton SR, Preisinger AC, Nakamura Y and
White R (1989) Allelotype of colorectal carcinomas. Science 244: 207–211
Yonehara S, Ishii A and Yonehara M (1989) A cell-killing monoclonal antibody
(anti-Fas) to a cell surface antigen co-down-regulated with the receptor of
tumor necrosis factor. J Exp Med 169: 1747–1756
The Fas gene is not methylated in colonic tumours 135
British Journal of Cancer (2000) 82(1), 131–135 © 2000 Cancer Research Campaign